UroGen Receives New U.S. Patent Allowance For Next-Generation Mitomycin-Based Products Expected To Provide Protection Until December 2041
UroGen Receives New U.S. Patent Allowance For Next-Generation Mitomycin-Based Products Expected To Provide Protection Until December 2041
- Once issued, this patent provides U.S. intellectual property coverage of UroGen's RTGel technology with medac lyophilized mitomycin formulation, covering UGN-103 and UGN-104 development programs until December 2041
- 一旦頒發，該專利將爲烏龍製藥的RTGel技術和medac凍乾式絲裂黴素製劑提供美國知識產權保護，涵蓋UGN-103和UGN-104開發計劃，有效期至2041年12月。
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application no. 18/535,108 entitled "Material and Method for Treating Cancer."
烏龍製藥有限公司（納斯達克股票代碼：URGN），一家致力於開發和商業化治療尿路上皮癌和特殊癌症創新解決方案的生物技術公司，今天宣佈已收到美國專利和商標局（USPTO）對申請號爲18/535,108的名爲「治療癌症的材料和方法」的專利申請的批准通知。
The allowed claims relate to the combination of UroGen's RTGel technology with medac's licensed proprietary lyophilized mitomycin formulation and cover the use of UroGen's UGN-103 and UGN-104 development programs in the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) and low-grade upper tract urothelial cancer (LG-UTUC), respectively. The U.S. patent, once issued, will have an expiration date in December 2041.
允許的權利要求涉及烏龍製藥的RTGel技術與medac授權的獨有的凍乾式絲裂黴素製劑的組合，並涵蓋了在治療低級別中風險非肌層浸潤性膀胱癌（LG-IR-NMIBC）和低級別上尿路上皮癌（LG-UTUC）方面利用烏龍製藥的UGN-103和UGN-104開發計劃。該美國專利一旦頒發，將於2041年12月到期。
